Nano-based theranostics for chronic obstructive lung diseases: Challenges and therapeutic potential

Expert Opinion on Drug Delivery

Volumn 8, Issue 9, 2011, Pages 1105-1109

  Vij, Neeraj ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CF and COPD; Nano; Theranostic; Therapeutics

Indexed keywords

ANTIBIOTIC AGENT; CIGARETTE SMOKE; CORTICOSTEROID; GOLD NANOPARTICLE; MACROGOL; MACROGOL 2000; NANOCARRIER; NANOPARTICLE; POLYGLACTIN; POLYVINYL ALCOHOL; PREDNISOLONE; PROTEINASE; THEOPHYLLINE;

AIRWAY; ASTHMA; CHEMOTAXIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG EMPHYSEMA; MUCUS SECRETION; REVIEW; SUSTAINED DRUG RELEASE; TARGET CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 80052086371     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.597381     Document Type: Review

References (36)

1. Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999;103:309-12. (Pubitemid 29069979)
2. Roy I, Vij N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 2010;6:237-44
3. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88 (Pubitemid 37258549)
4. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-48. (Pubitemid 39658462)
5. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546-56
6. Ulrich M, Worlitzsch D, Viglio S, et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros 2010;9:217-27
7. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008;31:1334-56
8. Larsson K. Aspects on pathophysiological mechanisms in COPD. J Intern Med 2007;262:311-40 (Pubitemid 47246974)
9. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009;71:451-64
10. Barnes PJ. Theophylline for COPD. Thorax 2006;61:742-4 (Pubitemid 44369394)
11. Hirano T, Yamagata T, Gohda M, et al. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. Thorax 2006;61:761-6 (Pubitemid 44369399)
12. Ramsdell J. Use of theophylline in the treatment of COPD. Chest 1995;107:206S-9S
13. Culpitt SV, de Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1371-6 (Pubitemid 34522939)
14. Vij N, Min T, Marasigan R, et al. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnology 2010;8:22
15. Yang W, Peters JI, Williams RO III. Inhaled nanoparticles-a current review. Int J Pharm 2008;356:239-47
16. Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005;11:56-62 (Pubitemid 40215838)
17. Davis SS. Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 1997;15:217-24 (Pubitemid 27242747)
18. Fang J, Sawa T, Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003;519:29-49 (Pubitemid 36577698)
19. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994;263:1600-3 (Pubitemid 24128361)
20. Sahoo SK, Panyam J, Prabha S, et al. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002;82:105-14 (Pubitemid 34775052)
21. Kurmi BD, Kayat J, Gajbhiye V, et al. Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2010;7:781-94.
22. Verbavatz JM, Ma T, Gobin R, et al. Absence of orthogonal arrays in kidney, brain and muscle from transgenic knockout mice lacking water channel aquaporin-4. J Cell Sci 1997;110(Pt 22):2855-60 (Pubitemid 27514114)
23. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett 2008;8:2851-7
24. Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008;2:889-96
25. Alavi A, Reivich M. Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med 2002;32:2-5 (Pubitemid 34112938)
26. Vos FJ, Bleeker-Rovers CP, Corstens FH, et al. FDG-PET for imaging of non-osseous infection and inflammation. Q J Nucl Med Mol Imaging 2006;50:121-30 (Pubitemid 44054877)
27. Chen DL, Rosenbluth DB, Mintun MA, et al. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol 2006;100:1602-9
28. Love C, Tomas MB, Tronco GG, et al. FDG PET of infection and inflammation. Radiographics 2005;25:1357-68 (Pubitemid 41695350)
29. Kuo PH, Carlson KR, Christensen I, et al. FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. Mol Imaging Biol 2008;10:306-14
30. Kuo PH, McClennan BL, Carlson K, et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol 2008;10:74-81
31. Wu Y, Kotzer CJ, Makrogiannis S, et al. A Noninvasive [(99m)Tc]DTPA SPECT/ CT Imaging methodology as a measure of lung permeability in a guinea pig model of COPD. Mol Imaging Biol 14 Sep 2010. [Epub ahead of print]
32. Katyal S, Kramer EL, Noz ME, et al. Fusion of immunoscintigraphy single photon emission computed tomography (SPECT) with CT of the chest in patients with non-small cell lung cancer. Cancer Res 1995;55:5759s-63s.
33. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
34. Kubota R, Yamada S, Kubota K, et al. Autoradiographic demonstration of 18F-FDG distribution within mouse FM3A tumor tissue in vivo. Kaku Igaku 1992;29:1215-21 (Pubitemid 23005003)
35. Leevy WM, Lambert TN, Johnson JR, et al. Quantum dot probes for bacteria distinguish Escherichia coli mutants and permit in vivo imaging. Chem Commun (Camb) 2008;20:2331-3 (Pubitemid 351691997)
36. Leevy WM, Gammon ST, Jiang H, et al. Optical imaging of bacterial infection in living mice using a fluorescent near-infrared molecular probe. J Am Chem Soc 2006;128:16476-7 (Pubitemid 46032707)